Development of DNA intercalative, HSA binder pyridine‐based novel Schiff base Cu(II), Ni(II) complexes with effective anticancer property: A combined experimental and theoretical approach

• Published in: Applied organometallic chemistry 2022-01, Vol.36 (1), p.n/a
• Main Authors: Satapathi, Dibyendu, Das, Manik, Rajak, Karunamoy, Laha, Soumik, Islam, Md. Maidul, Choudhuri, Indranil, Bhattacharyya, Nandan, Das, Sinjan, Samanta, Bidhan Chandra, Maity, Tithi
• Format: Article
• Language: English
• Subjects: Anticancer properties; anticancer property; Binding; Cancer; Cell death; Chemistry; Coordination compounds; Copper; Density functional theory; DFT; Dichroism; DNA; Fluorescence; HAS binding; Imines; metal complex; Molecular docking; Nickel; Oxidation; Pyridines; Serum albumin; Titration calorimetry; Toxicity; Valence
• ISSN: 0268-2605; 1099-0739
• DOI: 10.1002/aoc.6473

The two novel Cu(II) complexes [Cu(L)(CH3COO)] and [Cu(L)(N3)] (1, 2) and one Ni(II) complex [Ni(L)(N)3] (3) have been developed by using the ligand HL, obtained by the condensation of 2 amino methyl pyridine and 5‐bromo salicylaldehyde. All the three complexes are spectroscopically characterized along with molar conductance measurement. With the help of EPR, density functional theory (DFT) studies, the occupants of distorted square planer geometry with azide (2 and 3), acetate (1) as a secondary anionic residue, and the presence of +2 oxidation state on metal center of the complexes have been documented. After structural determination, all the complexes have been exposed to inspect their DNA and human serum albumin (HSA) binding efficacy. Initially, the higher binding constants, obtained from electronic titration among complexes and DNA, the impressive reduction of fluorescence intensities of the HSA and Ethidium Bromide (EtBr)‐DNA adduct, after incremental addition of complexes separately, assure the high binding ability of complexes 2 and 3 in compare with 1. The time‐dependent fluorescence study, isothermal titration calorimetry (ITC), and circular dichroism (CD) spectral titration provide the additional support to get affirmation about the binding potentiality of the aforementioned complexes with DNA/HSA. The molecular docking study authenticates the experimental approach. Furthermore, the anticancer study of all the complexes has been checked by implementing the MTT assay method on two cancer cell lines and one normal cell line. The MTT assay results explore the better anticancer property of complex 2 in comparison with complexes 1 and 3 with low toxicity to the normal cell, and this fact may be correlated with the impressive DNA and HSA binding efficacy of complex 2. Finally, the nuclear staining study by AO/PI dual sensor discloses the nuclear morphological change of cancer cells along with the opening of cell death mechanism, suggesting the apoptotic pathway. Development of three new Cu(II) and Ni(II) complexes based on pyridine‐salicylaldehyde platform with effective DNA/HSA binding efficacy and anticancer property: a merge effect of theory and experiment.